The Validation Master Plan is the overarching document that structures a manufacturing site’s qualification and validation program. It describes the policy, responsibilities, systems, facilities, processes and their status, as well as the approach to changes, deviations, acceptance criteria and, where applicable, requalification. The plan thus creates the site-wide context within which individual validation protocols and reports are situated.<\/p>\n
Annex 15 requires that the key elements of the site’s qualification and validation program be clearly defined and documented in a Validation Master Plan or equivalent document. The plan is not a collection of already completed evidence. It sets out the rules by which the site controls its critical facilities, equipment, utility systems, computerized systems and manufacturing processes throughout their lifecycle.<\/p>\n
Expected contents include the qualification and validation policy, the organizational structure including roles and responsibilities, an overview of facilities, equipment, systems and processes together with their qualification or validation status, and the strategy including requalification, where applicable. The master plan also references existing documents and defines how acceptance criteria are developed.<\/p>\n
Planning is risk-based. Annex 15 requires that the scope and extent of qualification and validation be based on a justified and documented risk assessment. The master plan ensures that these assessments are not developed in isolation for individual pieces of equipment, but instead fit into the site’s overall strategy and its change control.<\/p>\n
The Validation Master Plan describes how changes and deviations within the qualification and validation program are handled. Planned changes to facilities, equipment, utility systems or processes that may affect product quality must be formally documented and assessed with respect to the validated state or the control strategy. The plan assigns roles, decision points and the link to the subsequent protocols for this purpose.<\/p>\n
A site may identify new risks as knowledge grows or through a development project. Annex 15 requires that risk assessments be repeated when necessary and that their use in qualification and validation work be clearly documented. As a result, the master plan does not remain fixed at the initial equipment inventory, but shows how requalification, supplementary testing or revised acceptance criteria are incorporated into the program.<\/p>\n
For large and complex projects, separate validation plans can also be useful. They improve clarity for a given project but do not replace the site’s Validation Master Plan. The exception of concurrent validation, if considered due to a strong benefit-risk ratio, must be justified, documented visibly in the master plan, and approved by authorized personnel.<\/p>\n
The Validation Master Plan is the upstream planning level for the entire site. A validation protocol, by contrast, describes the specific testing of a particular system, process or project, including critical parameters and predefined acceptance criteria. The subsequent report summarizes the results, deviations and conclusion of that specific execution.<\/p>\n
The existing entry validation refers to the technical confirmation that a process or system fulfills its intended purpose; validation refers to the same core concept. The Validation Master Plan does not itself provide this evidence. It defines which evidence, responsibilities and strategic repetitions are required at the site. For this reason, a single successful protocol cannot substitute for a missing master plan.<\/p>\n
When manufacturing investigational medicinal products, the Validation Master Plan provides the framework for assessing, in a traceable manner, the status of the facilities, processes and systems used for a given batch. Development-typical adaptations may be permissible, but must be evaluated against the manufacturing site’s qualification and validation status. For batch certification, what matters is whether the facilities and methods used were maintained in the appropriate controlled status.<\/p>\n
Full-service CROs such as Mediconomics support the interface between study requirements and manufacturing planning, for example by promptly relaying changes to the protocol, dosage form, packaging or logistics to the relevant quality and manufacturing functions. They can also coordinate documentation requirements for investigational medicinal products, without assuming the manufacturer’s responsibility for its Validation Master Plan or technical validation.<\/p>\n
The master plan may reference existing documents, but it must make their interplay clearly understandable. An inventory without status information, or a list of SOPs without a strategy, is not sufficient to provide a clear picture of the site’s qualification and validation program.<\/p>\n
Is a Validation Master Plan written for each individual product?<\/strong><\/p>\n No. It structures the qualification and validation program of a site. Product- or project-specific requirements are addressed through individual plans, protocols and reports beneath it.<\/p>\n What distinguishes a master plan from a validation protocol?<\/strong><\/p>\n The master plan describes the strategy, scope, roles and status within the overall program. The protocol defines the specific execution and acceptance criteria for an individual qualification or validation activity.<\/p>\n Where is requalification addressed?<\/strong><\/p>\n The qualification and validation strategy in the Validation Master Plan should include requalification where applicable. The individual measures are then planned and documented in specific documents.<\/p>\n The Validation Master Plan is the overarching document that structures a manufacturing site’s qualification and validation program. It describes the policy, responsibilities, systems, facilities, processes and their status, as well as the approach to changes, deviations, acceptance criteria and, where applicable, requalification. The plan thus creates the site-wide context within which individual validation protocols and […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[26],"class_list":["post-8194","glossary","type-glossary","status-publish","hentry","glossary-cat-gmp-qualitaet-herstellung"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8194","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8194\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=8194"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=8194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n